HL
REGN icon

Harding Loevner’s Regeneron Pharmaceuticals REGN Stock Holding History

Harding Loevner’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-11
Closed -$8K – 140
2022
Q3 		$8K Buy
+11
New +$6.92K ﹤0.01% 158
2021
Q3 		– Sell
-11
Closed -$6K – 160
2021
Q2 		$6K Hold
11
– – ﹤0.01% 150
2021
Q1 		$5K Sell
11
-15
-58% -$7.3K ﹤0.01% 153
2020
Q4 		$13K Sell
26
-2
-7% -$1.08K ﹤0.01% 139
2020
Q3 		$16K Sell
28
-1
-3% -$606 ﹤0.01% 163
2020
Q2 		$18K Sell
29
-16,718
-100% -$9.49M ﹤0.01% 122
2020
Q1 		$8.18M Sell
16,747
-590,595
-97% -$244M 0.05% 70
2019
Q4 		$228M Sell
607,342
-84,936
-12% -$28.6M 1.01% 33
2019
Q3 		$192M Buy
692,278
+2,858
+0.4% +$846K 0.91% 39
2019
Q2 		$216M Sell
689,420
-9,902
-1% -$3.3M 0.99% 33
2019
Q1 		$287M Buy
699,322
+18,591
+3% +$7.66M 1.35% 24
2018
Q4 		$254M Buy
680,731
+43,833
+7% +$16M 1.47% 24
2018
Q3 		$257M Buy
636,898
+18,259
+3% +$6.95M 1.34% 27
2018
Q2 		$213M Sell
618,639
-6,925
-1% -$2.17M 1.2% 29
2018
Q1 		$216M Sell
625,564
-6,347
-1% -$2.21M 1.12% 32
2017
Q4 		$238M Sell
631,911
-15,866
-2% -$6.43M 1.35% 27
2017
Q3 		$290M Buy
647,777
+116,195
+22% +$55.3M 1.65% 19
2017
Q2 		$261M Sell
531,582
-25,818
-5% -$11.3M 1.6% 21
2017
Q1 		$216M Buy
557,400
+242,162
+77% +$89.8M 1.41% 26
2016
Q4 		$116M Sell
315,238
-3,327
-1% -$1.27M 0.81% 48
2016
Q3 		$128M Buy
318,565
+152,425
+92% +$61.1M 0.92% 45
2016
Q2 		$58M Buy
+166,140
New +$64M 0.45% 59

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Harding Loevner's REGN Position: Q4 2022 in Review

Harding Loevner sold out of Regeneron Pharmaceuticals (REGN) in Q4 2022, closing a stake of 11 shares — an estimated $8K sold.

Harding Loevner first reported a position in REGN in Q2 2016 and held it in 22 quarters. The position peaked at $290M in Q3 2017. 1,160 funds tracked by Wall St. Rank hold REGN as of Q4 2022.

  • Harding Loevner reported no remaining Regeneron Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Harding Loevner sold 11 Regeneron Pharmaceuticals shares in Q4 2022, an estimated $8K.
  • Harding Loevner first reported a position in Regeneron Pharmaceuticals in Q2 2016 and held it in 22 quarters.
  • Harding Loevner's Regeneron Pharmaceuticals position peaked at $290M in Q3 2017.
  • 1,160 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2022.

Based on Harding Loevner's 13F filing for Q4 2022, filed 14 Feb 2023.